133 related articles for article (PubMed ID: 36924035)
1. Characterization of ionic strength for X-MuLV inactivation by low pH treatment for monoclonal antibody purification.
Daya J; Cusick V; Mattila J
Biotechnol Bioeng; 2023 Jun; 120(6):1605-1613. PubMed ID: 36924035
[TBL] [Abstract][Full Text] [Related]
2. Characterization of operating parameters for XMuLV inactivation by low pH treatment.
Chinniah S; Hinckley P; Connell-Crowley L
Biotechnol Prog; 2016; 32(1):89-97. PubMed ID: 26488618
[TBL] [Abstract][Full Text] [Related]
3. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins.
Brorson K; Krejci S; Lee K; Hamilton E; Stein K; Xu Y
Biotechnol Bioeng; 2003 May; 82(3):321-9. PubMed ID: 12599259
[TBL] [Abstract][Full Text] [Related]
4. The Use of Bayesian Hierarchical Logistic Regression in the Development of a Modular Viral Inactivation Claim.
Banton D; Vacante D; Bulthuis B; Goldstein J; Wineburg M; Schreffler J
PDA J Pharm Sci Technol; 2019; 73(6):552-561. PubMed ID: 31101710
[TBL] [Abstract][Full Text] [Related]
5. Low pH inactivation for xenotropic gamma retrovirus in recombinant human TNF-α receptor immunoglobulin G and mechanism of inactivation.
Ma R; Cui X
Biologicals; 2014 Jan; 42(1):52-6. PubMed ID: 24341971
[TBL] [Abstract][Full Text] [Related]
6. Continuous low pH viral inactivation: Operation and scaling strategy informs viral clearance study.
Brown M; Godfrey S; Creasy A; Salm J; Fahrner R
Biotechnol Bioeng; 2022 Aug; 119(8):2115-2121. PubMed ID: 35470424
[TBL] [Abstract][Full Text] [Related]
7. pH inactivation of SARS-CoV-2 and SARS-CoV in virus spiked protein A eluates from a mAb purification process.
Limburg H; Schwerdtner M; Wilson E; Roth B; Cassart JP; Werner AD; Harbig A; Böttcher-Friebertshäuser E; Stokes A
Biologicals; 2024 May; 86():101753. PubMed ID: 38492418
[TBL] [Abstract][Full Text] [Related]
8. Virus study for continuous low pH viral inactivation inside a coiled flow inverter.
David L; Maiser B; Lobedann M; Schwan P; Lasse M; Ruppach H; Schembecker G
Biotechnol Bioeng; 2019 Apr; 116(4):857-869. PubMed ID: 30450694
[TBL] [Abstract][Full Text] [Related]
9. Understanding mAb aggregation during low pH viral inactivation and subsequent neutralization.
Wälchli R; Ressurreição M; Vogg S; Feidl F; Angelo J; Xu X; Ghose S; Jian Li Z; Le Saoût X; Souquet J; Broly H; Morbidelli M
Biotechnol Bioeng; 2020 Mar; 117(3):687-700. PubMed ID: 31784982
[TBL] [Abstract][Full Text] [Related]
10. Quantitative competitive reverse transcription-PCR as a method to evaluate retrovirus removal during chromatography procedures.
Lau AS; Lie YS; Norling LA; Sernatinger J; Dinowitz M; Petropoulos CJ; Xu Y
J Biotechnol; 1999 Oct; 75(2-3):105-15. PubMed ID: 10553652
[TBL] [Abstract][Full Text] [Related]
11. Application of machine learning methods to pathogen safety evaluation in biological manufacturing processes.
Panjwani S; Cui I; Spetsieris K; Mleczko M; Wang W; Zou JX; Anwaruzzaman M; Liu S; Canales R; Hesse O
Biotechnol Prog; 2021 May; 37(3):e3135. PubMed ID: 33527773
[TBL] [Abstract][Full Text] [Related]
12. Limits in virus filtration capability? Impact of virus quality and spike level on virus removal with xenotropic murine leukemia virus.
Roush DJ; Myrold A; Burnham MS; And JV; Hughes JV
Biotechnol Prog; 2015; 31(1):135-44. PubMed ID: 25395156
[TBL] [Abstract][Full Text] [Related]
13. Cation exchange chromatography provides effective retrovirus clearance for antibody purification processes.
Connell-Crowley L; Nguyen T; Bach J; Chinniah S; Bashiri H; Gillespie R; Moscariello J; Hinckley P; Dehghani H; Vunnum S; Vedantham G
Biotechnol Bioeng; 2012 Jan; 109(1):157-65. PubMed ID: 21837666
[TBL] [Abstract][Full Text] [Related]
14. [Optimization and application of caprylic acid precipitation in the purification of monoclonal antibody].
Yang Z; Zhou J
Sheng Wu Gong Cheng Xue Bao; 2023 Sep; 39(9):3757-3771. PubMed ID: 37805852
[TBL] [Abstract][Full Text] [Related]
15. Real time quantitative PCR as a method to evaluate xenotropic murine leukemia virus removal during pharmaceutical protein purification.
Shi L; Chen Q; Norling LA; Lau AS; Krejci S; Xu Y
Biotechnol Bioeng; 2004 Sep; 87(7):884-96. PubMed ID: 15334415
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the viral clearance ability of continuous monoclonal antibody purification steps, in order to inactivate and/or remove four model viruses.
Rasouli-Nejad Mousavi SM; Hosseini SM; Ansari S
Iran J Microbiol; 2023 Oct; 15(5):711-722. PubMed ID: 37941874
[TBL] [Abstract][Full Text] [Related]
17. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
18. Development of a modular virus clearance package for anion exchange chromatography operated in weak partitioning mode.
Iskra T; Sacramo A; Gallo C; Godavarti R; Chen S; Lute S; Brorson K
Biotechnol Prog; 2015; 31(3):750-7. PubMed ID: 25826186
[TBL] [Abstract][Full Text] [Related]
19. Effect of pH, NaCl concentration, and mAb concentration of feed solution on the filterability of Planova™ 20N and Planova™ BioEX.
Hashikawa-Muto C; Yokoyama Y; Hamamoto R; Kobayashi K; Masuda Y; Nonaka K
Biotechnol Prog; 2024; 40(2):e3420. PubMed ID: 38146091
[TBL] [Abstract][Full Text] [Related]
20. Quality by design approach for viral clearance by protein a chromatography.
Zhang M; Miesegaes GR; Lee M; Coleman D; Yang B; Trexler-Schmidt M; Norling L; Lester P; Brorson KA; Chen Q
Biotechnol Bioeng; 2014 Jan; 111(1):95-103. PubMed ID: 23860745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
